About Curatis AG
Founded in 2002 by experienced industry executives, Curatis AG is a privately owned speciality pharmaceutical company engaged in two business areas:
Curatis acquires, licences, distributes and promotes medicines for the treatment and/or prevention of rare and speciality diseases in Switzerland.
Curatis develops novel speciality care and orphan drugs for neurological disorders based on the principle of repurposing.
Günter Graubach - Founder & Chairman
Previously CURATIS's Chief Executive Officer, held various commercial management positions at Speciality European Pharma, MyoContract (now Santhera Pharmaceuticals) and Hoffmann-La Roche in Europe, USA, and Latin America; graduated with a Master's Degree in Business from the University of Lyon, France and a post graduate degree in Economics from the University of Constance, Germany.
Dr. Roland Rutschmann - Chief Executive Officer
Previously Vice President/General Manager at Orphan Europe in Paris (France), Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Worked for Hoffmann-La Roche and Warner-Lambert in Switzerland, The Netherlands and Germany in various managerial marketing and sales positions. Holds a PhD in Cell Biology/Immunology from the University of Basle. Attained commercial education at INSEAD and is Alumni of the INSEAD AMP.
Prof. Klaus Kutz, M.D. - Chief Development Officer
Over ten years of experience as independent consultant in early clinical development for pharmaceutical companies and clinical research organizations. More than 12 years experience as Head of Clinical Pharmacology with world-wide responsibilities for Phase I and Clinical Pharmacokinetics at Sandoz Pharma Ltd and Sanofi Research. A specialist for Internal Medicine, Gastroenterology and Clinical Pharmacology, he is also Professor of Medicine at the University of Bonn, Germany.
Prof. Klaus D. Döhler, Ph.D
Founder and Managing Director of Curatis Pharma GmbH, Hannover, Germany; previously commercial and R&D management positions at various German biotech and pharmaceutical companies; research in endocrinology at Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany, University School of Medicine, Hannover, Germany and University of California Brain Research Institute, Los Angeles, USA; holds a B.A. in Psychology and an M.A. in Biology from California State University, Fresno, USA and a Ph.D. from the University of Göttingen, Germany.
Dr. Herman Kempen
Head of research and drug discovery teams in the area of lipids and atherosclerosis for 18 years, published 90 papers and several patents. Gaubius Institute TNO, Leiden, member of the institute’s Management Team and leader of the Lipid and Atherosclerosis Group. Recruited to head up the Biology Department Metabolic Diseases Research at F. Hoffmann-La Roche in Basel. Broad business development and licensing experience and extensive network in the cardiovascular field (Roche, Speedel, LODH, ultreia).
Prof. Jes Olesen, M.D.
Professor of Neurology at University of Copenhagen and former chief of Danish Headache Center at the Department of Neurology, Glostrup University Hospital. One of the most recognized leading headache researchers in the world and instrumental in developing the standards of Headache Classification: Professor Olesen is the chairman of the classification committee. He led the first trials for triptans, NOS inhibitors and CGRP antagonists in migraine. Professor Olesen chairs a large research group with major projects in most areas of headache research. Other research interests include SPECT studies of cerebral blood flow and transcranial doppler studies, focusing on the pharmacology of the cerebral circulation. Professor Olesen has received many national and international prizes including honorary doctorates e.g. the University of Rome (2001). Leadership positions in numerous scientific societies, including President of International Headache Society (1993-1995), European Federation of Neurological Societies (1995-2001) and European Brain Council (2000). Honorary member of the Austrian-, French- and British Neurological Societies as well as a fellow of the Royal College of Physicians. Has authored or co-authored more than 500 papers and book chapters and has edited or written more than 20 books, most recently "The Classification and Diagnosis of Headache Disorders".
Prof. Arnim Pause, M.Sc., Ph.D.
Canada Research Chair for Molecular Oncology at Goodman Cancer Research Center and Department of Biochemistry, McGill University, Montreal, Canada; scientific advisor and consultant for pharmaceutical and biotechnology companies; previously held Research and Development management positions at Boehringer Ingelheim and Max-Plank Institute for Biochemistry, Martinsried, Germany; graduated with an M.Sc. Degree in Molecular Biology from the University of Constance, Germany, followed by a Ph.D. Degree in Biochemistry from McGill University and a postdoctoral fellowship at the National Institutes of Health, USA.